Major participants in this segment include McKesson Corporation, Cencora, Cardinal Health, along with manufacturers such as Sandoz, Teva Pharmaceuticals, Viatris, Sun Pharma, and Fosun Pharma
Dual-energy X-ray absorptiometry (DEXA) was used to assess changes in body composition in 171 participants in the active treatment groups
They may be able to help you access discounts or suggest cost-effective alternatives that fit your budget
Key Points Semaglutide redefining diabetes and obesity treatment 2026: inflection point with patent expiries Manufacturing scalability remains a key constraint Generic entry limited by technical and regulatory barriers Next-generation therapies driving competitive pressure Executive Summary Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), led by semaglutide, have fundamentally transformed the global management of type 2 diabetes mellitus and obesity, delivering substantial improvements in glycemic control, sustained weight reduction, and cardiovascular risk mitigation